Pediatric Annals

Feature Article 

Drug Allergy

Divya Seth, MD; Deepak Kamat, MD, PhD

Abstract

Drug allergy is commonly encountered in clinical practice. It is an immunological response to a pharmaceutical agent. The clinical presentation can vary from mild cutaneous reactions to life-threatening conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Diagnosis is most often clinical, but investigations such as measurement of immunoglobulin E, patch testing, and skin biopsy may be required. In patients with a known drug allergy, the offending drug should be avoided. [Pediatr Ann. 2018;47(10):e419–e425.]

Abstract

Drug allergy is commonly encountered in clinical practice. It is an immunological response to a pharmaceutical agent. The clinical presentation can vary from mild cutaneous reactions to life-threatening conditions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Diagnosis is most often clinical, but investigations such as measurement of immunoglobulin E, patch testing, and skin biopsy may be required. In patients with a known drug allergy, the offending drug should be avoided. [Pediatr Ann. 2018;47(10):e419–e425.]

Drug allergy is defined as an immunological response to a pharmaceutical and/or formulation (excipient) agent in a sensitized person.1 It is a type of adverse drug reaction and can present with variable clinical manifestations.

Mechanism of Drug Allergy

Various immunological mechanisms have been postulated for drug allergy (Table 1). These have been stratified based on classification by Gell and Coombs.1 Type I reactions are immediate-type reactions that are mediated by drug-specific immunoglobulin (Ig) E antibodies. Type I reactions can result in urticaria, angioedema, and even anaphylaxis in severe cases. Type II reactions are cytotoxic reactions mediated by drug-specific IgG or IgM antibodies. Type III reactions are immune complex-mediated reactions, and type IV or delayed-type hypersensitivity reactions are cell mediated.1 The classic reaction in type IV category is contact dermatitis in which symptoms are usually limited to the skin and can appear a few hours to 10 days after contact with the allergen. Other examples of type IV reactions include maculopapular exanthems and acute generalized exanthematous pustulosis.2

Immunological Classification of Drug Allergy

Table 1:

Immunological Classification of Drug Allergy

Clinical Manifestations

Drug allergy can affect multiple organ systems (Table 2). Cutaneous manifestations tend to be the most common; however, other organ systems, including gastrointestinal, pulmonary, hematologic, and renal, can also be involved.3 Skin involvement can vary from urticaria, angioedema, and exanthems to pustular or blistering lesions. Presence of urticaria and angioedema indicate an IgE-mediated etiology, whereas generalized exanthems are usually suggestive of delayed hypersensitivity. Thus, characterization of these cutaneous lesions can help in identifying the etiology and provide information for further evaluation. The most severe manifestations of skin involvement include Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and both of these are associated with high morbidity and mortality. Patients may present with fever, oral and ocular involvement, and epidermal detachment.3 The drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a multiorgan inflammatory response that can also be life-threatening. Symptoms can develop 2 to 8 weeks after initiation of therapy and may worsen after the offending drug is discontinued. Symptoms may persist for weeks or even months.4

Drug-Induced Allergic Reactions and Syndromes

Table 2:

Drug-Induced Allergic Reactions and Syndromes

Diagnosis

A thorough history should be obtained while evaluating patients with suspected drug allergies. History taking in such patients should focus on obtaining information regarding:

  1. Name of the offending drug

  2. Onset and duration of symptoms

  3. Clinical manifestations and involvement of various organ systems

  4. Concurrent infections—symptoms of the underlying infection may resemble drug allergy and the medication may be mistakenly blamed (eg, penicillin therapy for scarlet fever)

  5. Concurrent medications—opiates and nonsteroidal anti-inflammatory drugs (NSAIDs) frequently cause urticaria

  6. Previous exposure to the offending drug that was well tolerated—risk of allergic sensitization

  7. Past history of similar symptoms in the absence of drug treatment—patients diagnosed with chronic urticaria tend to develop hives even in the absence of the offending drug

  8. Exposure to the same or similar drug since the reaction

  9. Time since the initial reaction—allergy to some drugs (eg, penicillin) tends to resolve over time

Physical Examination

Physical examination should focus on all systems that could be involved in patients with drug allergy. Cutaneous involvement is the most common and can be variable. Generalized exanthems (maculopapular lesions) tend to be the most common.1 Other lesions include urticarial/angioedema, fixed drug eruptions, pustules, and target lesions/erythema multiforme. Patients should be monitored for any mucosal involvement (oral and genitourinary) and epidermal detachment as seen in patients with SJS and TEN. Eye involvement, lymphadenopathy, hepatosplenomegaly, and joint involvement (swelling/tenderness) should be evaluated.

Laboratory Evaluation

Routine laboratory testing has a limited role in evaluation of a patient with a suspected drug allergy. Because multiple organs may be involved, laboratory tests including complete blood count, liver enzymes, and kidney functions should be obtained. Complete blood count may show eosinophilia, but it is not diagnostic of a drug-induced allergic reaction.3

Type I or immediate-hypersensitivity reactions are mediated by drug-specific IgE antibodies. These can be demonstrated by in vivo (skin test) or in vitro (laboratory) assays. Currently, standardized and reliable skin test reagents are available only for the penicillins.1 Diagnostic testing is presently not available for most other medications. Specific IgE in vitro assays are available, but they are not adequately validated and hence not reliable.3 A radioallergosorbent test detects specific IgE antibodies and is based on radioimmunoassay. Another test is based on fluorescence enzyme-labeled assays and is a more sensitive test compared to the radioallergosorbent test. A third type of test uses enzyme-amplified chemiluminescent assay for detection of antibody or antigen.

A patch test for drugs can be helpful in evaluation of certain type IV or cell-mediated cutaneous drug reactions such as contact dermatitis, maculopapular exanthems, and fixed drug eruptions.5

The basophil activation test (BAT) is an in vitro assay that has been evaluated in patients with possible IgE-mediated drug allergies.6 Basophils are stimulated with an allergen (drug), which results in upregulation of specific markers in the basophils. These markers are then detected using specific antibodies in the laboratory. BAT has been used to evaluate IgE-mediated allergy to certain medications including beta-lactam antibiotics, NSAIDs, and muscle relaxants. However, only limited data are available presently regarding its efficacy.6

A skin biopsy may be helpful in some patients with severe or persistent reactions, although there are no definite diagnostic criteria of drug-induced reactions.7

Drug Allergic Reactions to Specific Agents

Beta-Lactam Antibiotics: Penicillins

Penicillin is the most common cause of drug allergy. About 10% of patients report penicillin allergy.3 However, penicillin-specific IgE antibodies tend to fade over time, so 90% of these patients are able to tolerate penicillins eventually.8 Patients are also often misdiagnosed as being allergic to penicillin because clinical manifestations of an underlying sickness may mimic allergic reaction to a drug. As a result, more expensive and broad-spectrum antibiotics are used, which can lead to development of drug-resistant bacteria, which results in higher health care costs.9

Penicillin tends to spontaneously metabolize and generate reactive intermediates that can bind to self-proteins and generate an immune response. These include the major antigenic determinant (penicilloyl moiety) and the minor antigenic determinants among which penicilloate and penilloate are the most important for inducing allergic responses.8

A penicillin skin test should be done using validated reagents if symptoms are consistent with IgE-mediated reactions.8 This should preferably be done when patients are doing well. The negative predictive value of the test is approximately 100% using both minor and major determinants for IgE-mediated reactions.1,3,8 A negative skin test response should always be followed by oral challenge with penicillin. A very small proportion of patients (1%–3%) with negative skin test responses developed mild reactions on being challenged with the drug.8 In the case of positive skin test, penicillin can be administered only after desensitization or induction of tolerance.

A history of reaction to penicillin is a poor predictor of who will have a positive response to a penicillin skin test. If a penicillin skin test is not available, the clinical decision should be based on reaction history. Patients with vague reactions or reactions more than 10 years ago are less likely to be allergic and penicillin can be administered through a graded challenge. In contrast, patients who have a history of anaphylaxis to penicillin should undergo desensitization.10

Patients who are allergic to the core beta-lactam group of penicillins tend to cross-react to all penicillin drugs. However, a small group of patients react selectively to particular penicillin compounds (eg, amoxicillin) and are able to tolerate other penicillin. This is due to allergy to the R-group side chain, which varies among different penicillins.11

Penicillin/Cephalosporin Cross-Reactivity

In the past, cephalosporin preparations frequently contained minute quantities of penicillin. This resulted in frequent reactions when patients with penicillin allergy were administered cephalosporins. However, there is no penicillin contamination in the cephalosporin preparations available presently. When possible, penicillin skin testing should be performed prior to cephalosporin administration in patients with a history of penicillin allergy. Patients with reported penicillin allergy and a positive penicillin skin test are at a higher risk of reaction to cephalosporins (6%) compared to patients with a negative skin test (0.7%).12

Patients who are allergic to amoxicillin should avoid cephalosporins, which have identical R-group side chains (cefadroxil), due to high cross-reactivity.13 Similarly, ampicillin and certain cephalosporins (cephalexin, cefaclor) also have an identical R-group side chain, so they should be avoided in patients with ampicillin allergy or those patients should receive them only after induction of drug tolerance.13

Sulfonamides

Sulfonamide antibiotics (tri-methoprim/sulfamethoxazole [TMP-SMX]) are a common cause of drug reactions, seen in up to 4% patients exposed to these medications.14 Delayed maculopapular/morbilliform eruptions are the most common manifestations.14 Sulfonamides are the also most common cause of SJS and TEN.15 They usually do not cause IgE-mediated reaction. Sulfonamide antibiotics differ structurally from non-antibiotic sulfonamides (ie, sulfasalazine, furosemide). Thus, there is no cross-reactivity between the antibiotic and non-antibiotic sulfonamides, so non-antibiotic sulfonamides can be safely given to patients who are allergic to sulfonamide antibiotics.16

People infected with HIV tend to develop generalized skin rash when they are exposed to sulfonamide antibiotics. This may be due to allergic sensitization related to their frequent use in people infected with HIV. Between 40% and 80% of HIV-infected patients develop rash with TMP-SMX, in contrast to 3% to 5% people not infected with HIV.14 The rash is usually maculopapular and itchy and tends to develop during the second week of treatment. TMP-SMX tends to be the treatment of choice for various HIV-associated infections, specifically infection with Pneumocystis jiroveci. In such patients, TMP-SMX can be safely administered using desensitization or drug tolerance procedures.17

NSAIDs

Reactions to NSAIDs can vary from IgE-mediated reactions (urticaria, angioedema, anaphylaxis) to non–IgE-mediated reactions (aspirin exacerbated respiratory disease [AERD], pneumonitis). Anaphylaxis to NSAIDs is usually drug-specific and other NSAIDs are well tolerated.18 Patients with AERD exhibit cross-reactivity to other NSAIDs.18

Local Anesthetics

Local anesthetics are broadly classified into two groups: benzoate esters (benzocaine) and amides (lidocaine). Although the benzoate esters exhibit cross-reactivity among each other, the amides do not. Local anesthetics usually do not cause IgE-mediated reactions.19 Most adverse reactions are related to anxiety associated with the injection or psychogenic response. Also, unintentional intravenous injection of the local anesthetic can result in overdose or toxic reaction.20 Occasionally, patients may be allergic to preservatives in local anesthetics.21 In these situations a preservative-free local anesthetic should be used.

Angiotensin-Converting Enzyme Inhibitor: Cough and Angioedema

Angiotensin-converting enzyme inhibitor (ACEI) use is commonly associated with adverse effects such as cough and angioedema. ACEI-associated cough can affect 5% to 35% patients.22 It is seen more commonly in women and nonsmokers. Onset of cough can be early, within hours of the first dose, or may be delayed for weeks or months. It usually resolves in 1 to 4 weeks upon stopping the medication.22

ACEI-induced angioedema tends to affect the head and neck region, especially the lips and tongue. It is a common cause of ED visit for angioedema in adults, accounting for up to one-third of these patients.23 Onset of symptoms can vary from a few hours to 10 years after starting treatment, with a mean of 1.8 years.24 Angioedema in these patients is mediated by bradykinin, thus there is no associated urticaria and pruritis.25 These patients tend to tolerate angiotensin II receptor blockers well.

Radio-Contrast Media

Adverse effects related to the use of radio-contrast media (RCM) are usually non IgE-mediated (anaphylactoid). Most of the effects are due to direct effects of RCM on mast cells and basophils. This results in release of the mediators, which can cause anaphylactoid reactions. These occur in about 1% to 3% of patients who receive ionic radiocontrast media and <0.5% of patients who receive nonionic agents.26 Ionic contrast media usually have higher osmolality and are thus associated with more side effects.27 Adverse reactions are more common in female patients, patients who have asthma or cardiovascular conditions, and those using beta-blockers.28

Patients with an allergy to seafood can safely receive iodinated RCM, as adverse reactions to RCM are unrelated to the iodine content of seafood.29

Occasionally patients may develop skin eruptions, which are T-cell mediated reactions, 1 week after the use of RCM.

HIV Medications

Patients infected with HIV are prone to develop drug-induced allergic reactions.30 TMP-SMX tends to be a common cause of drug reactions in these patients. Other antiretroviral drugs are also commonly involved. Patients with certain human leukocyte antigen (HLA) alleles are at a higher risk. Abacavir, which is a nucleoside reverse transcriptase inhibitor, can cause hypersensitivity reactions manifesting as fever, rash, gastrointestinal involvement, and respiratory involvement. HLA-B*5701 is associated with an increased risk for these reactions.31 Genetic screening prior to starting therapy has decreased the rate of abacavir-associated reactions.

Corticosteroids

The most common adverse effect associated with the use of corticosteroids is allergic contact dermatitis due to topical steroid preparations. Immediate hypersensitivity reactions to corticosteroids are rare. Most case reports mention intravenous methylprednisone and hydrocortisone as the culprit drug;32,33 patients can usually tolerate other corticosteroids. Preservatives and diluents are believed to be responsible for these reactions in some cases.33 Thus, skin testing should be done for the corticosteroid in question as well as for the preservative/diluent. Some of these reactions may be anaphylactoid in nature and a skin test would be negative in such cases.

Chemotherapeutic Agents

Adverse reactions to cancer chemotherapeutic agents can vary from mild skin eruptions to anaphylaxis.34 Platinum compounds (cisplatin and carboplatin) can cause immediate hypersensitivity reactions, usually after repeated exposures, whereas taxanes, such as paclitaxel, can cause anaphylactoid reactions with the first dose. These reactions can be prevented in more than 90% of cases with pretreatment by using antihistamines and corticosteroids.35 These drugs can, however, be safely administered using desensitization or induction of drug tolerance procedures.36

Biologic Modifiers

Biologic modifiers include cytokines, monoclonal antibodies, and interferons. These are immune modulatory agents and are used in treatment of various inflammatory conditions and tumors.

Interferons are associated with adverse reactions such as flu-like symptoms, depression, headache, and autoimmune reactions.37 IgE-mediated reactions may vary from urticaria to anaphylaxis.

Anti-tumor necrosis factor alpha agents such as infliximab and adalimumab are used for treatment of different inflammatory conditions such rheumatoid arthritis and Crohn's disease. Their use is associated with variable adverse reactions including urticaria, life-threatening anaphylaxis, and serum sickness.38 Guillain-Barre syndrome and other demyelinating syndromes have also been reported.39

Omalizumab has been approved for the treatment of asthma. It is a monoclonal antibody to human IgE. Occasionally, patients may develop anaphylaxis. Reactions usually occur within 2 hours of the injection and are more commonly seen with the first three doses.40

Intravenous gamma globulin can cause infusion reactions manifesting with fever, chills, headache, anxiety, myalgias, and occasionally hypotension. These reactions may occur 6 to 24 hours after an infusion.41

Complementary Medicines

Complementary medicines include herbal medicines, essential oils, bee pollen, vitamins, and minerals. These products are usually considered safe and natural; however, allergic reactions have been reported with some products such as bee pollen and echinacea (an herb).42,43 Some homeopathic products have been reported to cause systemic contact dermatitis in patients allergic to nickel.44 Thus, a history should always be obtained from patients regarding the use of any herbal products or supplements, including vitamins.

Management of Drug Allergy

Avoidance of the culprit drug is most important. All cross-reacting drugs should also be avoided. A “medic alert” bracelet can warn the treating physicians, who can then avoid the use of culprit drugs. It is important to make patients aware of their drug allergies, and their medical records should always be updated to include their drug allergy profile. Patients should also be provided with an epinephrine injector to be used in case of anaphylaxis. Sometimes, a particular drug may be life-saving or essential for optimal treatment of certain clinical conditions such as syphilis in pregnancy. In such cases, temporary drug tolerance can be achieved via desensitization.45 The drug can then be safely administered. A graded drug challenge can be done if the history is not suggestive of a drug allergy. In case of severe non–IgE-mediated reactions (ie, SJS, TEN, DRESS), induction of drug tolerance procedures is contraindicated.

In acute settings, the offending drug should be immediately stopped. In type 1 reactions, an epinephrine injector should be administered along with other emergency resuscitative measures. In the case of non–IgE-immediate reactions, treatment should be initiated with corticosteroids and antihistamines; however, in patients with advanced stages of SJS and TEN, corticosteroids are contraindicated. These patients should be managed in burn units instead. Intravenous immunoglobulin has also been shown to be helpful in some cases of SJS/TEN.46

References

  1. Solensky R, Khan DA, Bernstein IL, et al. Joint Task Force on Practice ParametersAmerican Academy of Allergy, Asthma and ImmunologyAmerican College of Allergy, Asthma and ImmunologyJoint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–273. doi:. doi:10.1016/j.anai.2010.08.002 [CrossRef]
  2. McKenna JK, Leiferman KM. Dermatologic drug reactions. Immunol Allergy Clin North Am. 2004;24:399–423. doi:. doi:10.1016/j.iac.2004.03.007 [CrossRef]
  3. Khan DA, Solensky R. Drug allergy. J Allergy Clin Immunol. 2010;125(2 suppl 2):S126–S137. doi:. doi:10.1016/j.jaci.2009.10.028 [CrossRef]
  4. Peyriere H, Dereure O, Breton H, et al. Network of the French Pharmacovigilance Centers. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?Br J Dermatol. 2006;155:422–428. doi:. doi:10.1111/j.1365-2133.2006.07284.x [CrossRef]
  5. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology. 2005;209:209–216. doi:. doi:10.1016/j.tox.2004.12.024 [CrossRef]
  6. Sanz ML, Gamboa PM, De Weck AL. Cellular tests in the diagnosis of drug hypersensitivity. Curr Pharm Des. 2008;14:2803–2808. doi:10.2174/138161208786369722 [CrossRef]
  7. Bronnimann M, Yawalkar N. Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?Curr Opin Allergy Clin Immunol. 2005;5(4):317–321. doi:10.1097/01.all.0000173787.65777.77 [CrossRef]
  8. Gadde J, Spence M, Wheeler B, Adkinson NF. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA. 1993;270:2456–2463. doi:10.1001/jama.1993.03510200062033 [CrossRef]
  9. Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. 2000;160:2819–2822. doi:. doi:10.1001/archinte.160.18.2819 [CrossRef]
  10. Sullivan TJ. Antigen-specific desensitization of patients allergic to penicillin. J Allergy Clin Immunol. 1982;69:500–508. doi:10.1016/0091-6749(82)90174-9 [CrossRef]
  11. Blanca M, Vega JM, Garcia J, et al. Allergy to penicillin with good tolerance to other penicillins: study of the incidence in sub-jects allergic to beta-lactams. Clin Exp Allergy. 1990;20:475–481. doi:10.1111/j.1365-2222.1990.tb03139.x [CrossRef]
  12. Park MA, Koch CA, Klemawesch P, et al. increased adverse drug reactions to cephalosporins in penicillin allergy patients with positive penicillin skin test. Int Arch Allergy Immunol. 2010;153:268–273. doi:. doi:10.1159/000314367 [CrossRef]
  13. Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol. 1996;98:671–677. doi:10.1016/S0091-6749(96)70101-X [CrossRef]
  14. Dibbern DA, Montanaro A. Allergies to sulfonamide antibiotics and sulfur-containing drugs. Ann Allergy Asthma Immunol. 2008;100:91–100. doi:. doi:10.1016/S1081-1206(10)60415-2 [CrossRef]
  15. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–1607. doi:10.1056/NEJM199512143332404 [CrossRef]
  16. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003;349:1628–1635. doi:. doi:10.1056/NEJMoa022963 [CrossRef]
  17. Solensky R. Drug desensitization. Immunol Allergy Clin North Am. 2004;24:425–443. doi:. doi:10.1016/j.iac.2004.03.008 [CrossRef]
  18. Quiralte J, Blanco C, Delgado J, et al. Challenge based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory drug- induced-reactions. J Investig Allergol Clin Immunol. 2007;17:182–188.
  19. Venemalm L, Degerbeck F, Smith W. IgE-mediated reaction to mepivacaine. J Allergy Clin Immunol. 2008;121:1058–1059. doi:. doi:10.1016/j.jaci.2007.12.1154 [CrossRef]
  20. Berkun Y, Ben-Zvi A, Levy Y, et al. Evaluation of adverse reactions to local anesthetics: experience with 236 patients. Ann Allergy Asthma Immunol. 2003;91:342–345. doi:. doi:10.1016/S1081-1206(10)61680-8 [CrossRef]
  21. Macy E, Schatz M, Zeiger RS. Immediate hypersensitivity to methylparaben causing false-positive results of local anesthetic skin testing or provocative dose testing. Permanente J. 2002;6:17–21.
  22. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 suppl):169S–173S. doi:. doi:10.1378/chest.129.1_suppl.169S [CrossRef]
  23. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100:327–332. doi:. doi:10.1016/S1081-1206(10)60594-7 [CrossRef]
  24. Malde B, Regalado J, Greenberger PA. Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol. 2007;98:57–63. doi:. doi:10.1016/S1081-1206(10)60860-5 [CrossRef]
  25. Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621–622. doi:. doi:10.1056/NEJM200208223470820 [CrossRef]
  26. Wolf GL, Mishkin MM, Roux SG, et al. Comparison of the rates of adverse drug reactions. Ionic contrast agents, ionic agents combined with steroids, and nonionic agents. Invest Radiol. 1991;26:404–410. doi:10.1097/00004424-199105000-00003 [CrossRef]
  27. Caro JJ, Trindale E, McGregor M. The risk of death and of severe nonfatal reactions with high- versus low-osmolality contrast media: a meta-analysis. Am J Roentgenol. 1991;156:825–832. doi:10.2214/ajr.156.4.1825900 [CrossRef]
  28. Lang DM, Alpern MB, Visintainer PF, et al. Gender risk for anaphylactoid reaction to radiographic contrast media. J Allergy Clin Immunol. 1995;95:813–817. doi:10.1016/S0091-6749(95)70123-0 [CrossRef]
  29. Schabelman E, Witting M. The relationship of radiocontrast, iodine, and seafood allergies: a medical myth exposed. J Emerg Med. 2010;39(5):701–707. doi:. doi:10.1016/j.jemermed.2009.10.014 [CrossRef]
  30. Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008;121:826–832.e5. doi:. doi:10.1016/j.jaci.2007.10.021 [CrossRef]
  31. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732. doi:10.1016/S0140-6736(02)07873-X [CrossRef]
  32. Peller JS, Bardana EJ. Anaphylactoid reaction to corticosteroid: case report and review of the literature. Ann Allergy. 1986;54:302–305.
  33. Freedman MD, Schocket AL, Chapel N, et al. Anaphylaxis after intravenous methylprednisolone administration. JAMA. 1981;245:607–608. doi:10.1001/jama.1981.03310310049024 [CrossRef]
  34. Castells MC. Hypersensitivity to antineoplastic agents. Curr Pharm Des. 2008;14:2892–2901. doi:10.2174/138161208786369803 [CrossRef]
  35. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12:2654–2666. doi:10.1200/JCO.1994.12.12.2654 [CrossRef]
  36. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122:574–580. doi:. doi:10.1016/j.jaci.2008.02.044 [CrossRef]
  37. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 suppl 1):112S–121S. doi:10.1002/hep.510260720 [CrossRef]
  38. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol Immunopathol (Madr). 2005;33:291–292. doi:10.1157/13080935 [CrossRef]
  39. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum. 2006;54:1429–1434. doi:. doi:10.1002/art.21814 [CrossRef]
  40. Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma & ImmunologyAmerican College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120:1373–1377. doi:. doi:10.1016/j.jaci.2007.09.032 [CrossRef]
  41. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122–132. doi:10.1007/s12026-007-0003-5 [CrossRef]
  42. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol. 2000;143:923–929. doi:10.1046/j.1365-2133.2000.03822.x [CrossRef]
  43. Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol. 2002;88:42–51. doi:. doi:10.1016/S1081-1206(10)63591-0 [CrossRef]
  44. de Medeiros LM, Fransway AF, Taylor JS, et al. Complementary and alternative remedies: an additional source of potential sys-temic nickel exposure. Contact Dermatitis. 2008;58:97–100. doi:. doi:10.1111/j.1600-0536.2007.01272.x [CrossRef]
  45. Wendel GD, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. N Engl J Med. 1985;312:1229–1232. doi:10.1056/NEJM198505093121905 [CrossRef]
  46. Tristani-Firouzi P, Petersen MJ, Saffle JR, et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47:548–552. doi:10.1067/mjd.2002.127249 [CrossRef]

Immunological Classification of Drug Allergy

TypeMechanismClinical FeaturesExamples of Offending Drugs
I (immediate hypersensitivity)Immunoglobulin E mediatedUrticaria, angioedema, bronchospasm, hypotension, anaphylaxisAntibiotics, chemotherapy (platinum compounds)
II (cytotoxic)Immunoglobulin G and immunoglobulin E mediatedHemolytic anemia and thrombocytopeniaSulfonamides, amino penicillins, quinidine
III (serum sickness)Immune-complex mediatedFever, rash, joint involvement, lymphadenopathyAminopenicillins, sulfonamide, antithymocyte globulin
IV (delayed hypersensitivity)Cell mediatedContact dermatitisNeomycin, topical corticosteroids, sulfonamides

Drug-Induced Allergic Reactions and Syndromes

Organ System InvolvedClinical FeaturesCommon Offending Drugs
SkinUrticaria/angioedemaAnitibiotics, NSAIDS
Maculo-papular eruptionsPenicillins, sulfonamide, anticonvulsants
Fixed drug eruptionsNSAIDs, tetracyclines
Acute generalized eczematous pustulosisAntimicribials, anticonvulsants, NSAIDs
Blistering disorders (SJS,TEN)Sulfonamides, allopurinol, anticonvulsants, NSAIDs
DRESS (fever, lymphadenopathy, rash, eosinophilia, elevated liver enzymes)Anticonvulsants, sulfonamides, minocycline
HepaticElevated liver enzymes, jaundiceSulfonamides, phenothiazines
PulmonaryLipoid pneumonia, fibrosis, pneumonitisNitrofurantoin, bleomycin, methotrexate, sulfonamides
RenalAcute Interstitial nephritis, glomerulonephritis, nephrotic syndromeMethicillin, sulfonamides, gold, NSAIDs, allopurinol
MusculoskeletalRhambomyolysis, tendon ruptureStatins, flouroquinolones
HematologicHemolytic anemia, thrombocytopeniaSulfonamides, penicillin
Authors

Divya Seth, MD, is an Assistant Professor, Division of Allergy/Immunology, Wayne State University School of Medicine, Children's Hospital of Michigan. Deepak Kamat MD, PhD, is a Professor of Pediatrics and Vice Chair for Education, Wayne State University School of Medicine; and a Designated Institutional Official, Children's Hospital of Michigan.

Address correspondence to Deepak Kamat, MD, PhD, Children's Hospital of Michigan, 3901 Beaubien Boulevard, Detroit, MI 48201; email: dkamat@med.wayne.edu.

Disclosure: The authors have no relevant financial relationships to disclose.

10.3928/19382359-20180920-02

Sign up to receive

Journal E-contents